Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
University of California, San Francisco
University of California, San Francisco
I-Mab Biopharma US Limited
Abramson Cancer Center at Penn Medicine
M.D. Anderson Cancer Center
OHSU Knight Cancer Institute
Centre Leon Berard
Eli Lilly and Company
AstraZeneca